IDEAYA Biosciences, Inc. Common Stock

IDYA trades at a $2.6B market cap despite being unprofitable (n/a P/E), suggesting the market is pricing in significant future earnings potential rather than current performance. With RSI at exactly 50.0, the stock sits in perfect equilibrium—neither overbought nor oversold—while 15.72% short interest indicates meaningful skepticism from bearish traders. Trading below its 52-week high provides some cushion, yet the combination of pre-profitability status and elevated short positioning creates potential squeeze dynamics if clinical data or catalysts ignite bullish momentum. The setup appears tension-laden: biotech believers versus cost-conscious shorts awaiting deeper discounts or disappointing results.